Advertisement
Advertisement
U.S. markets open in 8 hours 31 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
113.07+3.97 (+3.64%)
At close: 04:00PM EDT
113.20 +0.13 (+0.11%)
After hours: 07:59PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications

    Sarepta Therapeutics Inc (NASDAQ: SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone promises. Under the agreement, Sarepta will have the rights to five neuromuscular and cardiac indications, including Duchenne muscular dystrophy. According to Sarepta, the deal covers the MyoAAV program that aims to deliver more efficient gene therapies and at lower doses using modified capsids. Also Read: Sarepta's Duchenne Gene Therapy Up

  • GlobeNewswire

    Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases

    -Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four additional neuromuscular and cardiac indications -The MyoAAV platform is a potential breakthrough in genetic medicine delivery, with early research showing significantly greater gene expression at lower doses compared to natural serotype capsids CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the

  • Benzinga

    Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts

    Sarepta Therapeutics Inc (NASDAQ: SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward for SRP-9001 gene therapy for Duchenne muscular dystrophy. Last week, the company announced that it would seek accelerated approval for gene therapy. RBC Capital continues to see substantial share appreciation potential even on approval following Phase 3. The potential for accelerated approval provides additional upside optionality to expedite the d

Advertisement
Advertisement